Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hersch

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
Archives of Neurology|November 1, 1992
Treatment trial of oxiracetam in Alzheimer's diseaseR C Green, F C Goldstein, A P Auchus, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 1, 1997
Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatumR J Ferrante, C A Gutekunst, F Persichetti, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 23, 1999
Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathologyC A Gutekunst, S H Li, H Yi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 12, 1995
Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodiesC A Gutekunst, A I Levey, C J Heilman, et al.
Science (New York, N.Y.)|May 4, 2002
Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's diseaseAnthone W Dunah, Hyunkyung Jeong, April Griffin, et al.
Journal of Neurochemistry|September 28, 2004
Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregationJonathan H Fox, David S Barber, Bhupinder Singh, et al.
Molecular Neurodegeneration|June 24, 2010
The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's diseaseJonathan H Fox, Teal Connor, Vanita Chopra, et al.
Neurology|February 11, 2014
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington diseaseHerminia D Rosas, Gheorghe Doros, Sona Gevorkian, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 1, 1995
Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferentsS M Hersch, B J Ciliax, C A Gutekunst, et al.
Neurology|August 23, 2013
HTRF analysis of soluble huntingtin in PHAROS PBMCsMiriam Moscovitch-Lopatin, Rachel E Goodman, Shirley Eberly, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
Archives of Neurology|November 1, 1992
Treatment trial of oxiracetam in Alzheimer's diseaseR C Green, F C Goldstein, A P Auchus, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 1, 1997
Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatumR J Ferrante, C A Gutekunst, F Persichetti, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 23, 1999
Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathologyC A Gutekunst, S H Li, H Yi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 12, 1995
Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodiesC A Gutekunst, A I Levey, C J Heilman, et al.
Science (New York, N.Y.)|May 4, 2002
Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's diseaseAnthone W Dunah, Hyunkyung Jeong, April Griffin, et al.
Journal of Neurochemistry|September 28, 2004
Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregationJonathan H Fox, David S Barber, Bhupinder Singh, et al.
Molecular Neurodegeneration|June 24, 2010
The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's diseaseJonathan H Fox, Teal Connor, Vanita Chopra, et al.
Neurology|February 11, 2014
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington diseaseHerminia D Rosas, Gheorghe Doros, Sona Gevorkian, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 1, 1995
Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferentsS M Hersch, B J Ciliax, C A Gutekunst, et al.
Neurology|August 23, 2013
HTRF analysis of soluble huntingtin in PHAROS PBMCsMiriam Moscovitch-Lopatin, Rachel E Goodman, Shirley Eberly, et al.
Pageof 13